Are you stuck in a cycle of asthma attacks? You may have eosinophilic asthma. Find out what it is and what you can do to break the cycle.

The following is a summary of “Eosinophil count testing in patients with asthma varies by healthcare provider type in the US: ...

Interestingly, around 50% of patients with asthma also have a high number of circulating eosinophils. Patients with eosinophilic asthma tend to have more severe disease, and more frequent asthma ...

“Because eosinophils have a relatively high iron content, we wondered if we could combat asthma by selectively inducing eosinophil ferroptosis,” says Li. To test that idea, Li’s team ...

The antibody drug benralizumab is on the fast track to becoming the first new treatment for certain kinds of asthma and COPD flare-ups seen in 50 years, following promising clinical trial data.

Benralizumab can be used for the treatment of acute eosinophilic exacerbations of asthma and chronic obstructive pulmonary disease (COPD), according to a study published online Nov. 27 in The ...

Patients were given a quick blood test to see what type of attack ... being suitable for treatment. Around 50% of asthma attacks are eosinophilic exacerbations, as are 30% of COPD ones, according ...

Patients were given a blood test to check the type of attack ... were considered suitable for treatment. Around 50% of asthma attacks are eosinophilic exacerbations, as are 30% of COPD ones ...

Patients were given a quick blood test to see what type of attack ... being suitable for treatment. Around 50% of asthma attacks are eosinophilic exacerbations, as are 30% of COPD ones, according ...

may significantly improve outcomes during asthma and chronic obstructive pulmonary disease (COPD) exacerbations. Administering the drug via injection during eosinophilic exacerbations reduced the need ...

The antibody drug known chemically as benralizumab was approved by US and EU regulators in 2017 as a treatment for a severe form of the breathing disorder called eosinophilic asthma that targets a ...